DLC1 (deleted in liver cancer-1) is downregulated or deleted in colorectal cancer (CRC) tissues and functions as a potent tumor suppressor, but the underlying molecular mechanism remains elusive. We found that the conditioned medium (CM) collected from DLC1-overexpressed SW1116 cells inhibited the migration of colon adenocarcinoma cells HCT116 and SW1116, but had no effect on proliferation, which suggested DLC1-mediated secretory components containing a specific inhibitor for colon adenocarcinoma cell migration. Analysis by mass spectrometry identified mesencephalic astrocyte-derived neurotrophic factor (MANF) as a candidate. More importantly, exogenous MANF significantly inhibited the migration of colon adenocarcinoma cells HCT116 and SW1116, but did not affect proliferation. Mechanistically, DLC1 reduced the retention of MANF in ER by competing the interaction between MANF and GRP78. Taken together, these data provided new insights into the suppressive effects of DLC1 on CRC, and revealed the potential of MANF in the treatment of CRC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515611 | PMC |
| http://dx.doi.org/10.3389/fonc.2022.900166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rise in Minimally Invasive Surgery for Colorectal Cancer Is Associated With Adoption of Robotic Surgery.
Dis Colon Rectum
January 2025
Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Background: Minimally invasive surgery is associated with improved short-term outcomes and similar long-term oncologic outcomes for colorectal cancer patients compared with open surgery. Although the robotic approach has ergonomic and technical benefits, how it has impacted utilization of traditional laparoscopic surgery and minimally invasive surgery overall is unclear.
Objective: Describe trends in open, robotic, and laparoscopic approaches for colorectal cancer resections and examine factors associated with minimally invasive surgery.
Colonic polypectomy in 2024: hot or cold?
Acta Gastroenterol Belg
January 2025
Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.
Colorectal cancer (CRC) is the second and third leading cause of cancer death in men and women respectively worldwide. Colonoscopy is the gold standard screening test to detect premalignant lesions with endoscopic polypectomy preventing evolution to CRC. Endoscopic polypectomy is effective with a higher safety profile and is less costly as compared to surgery.
View Article and Find Full Text PDFIdentification of the oncogenic role and clinical implication of in Colon Adenocarcinoma.
J Cancer
January 2025
Department of Oncology, Geriatric Medical Center, Wuxi Second Geriatric Hospital, Wuxi Huishan Second People's Hospital, Wuxi, 214174, Jiangsu, China.
Colorectal carcinoma (CRC) is a highly prevalent and life-threatening disease with multi-stage progression, characterized by diverse molecular expression patterns at distinct stages, making treatment particularly challenging. Early detection and diagnosis of CRC are vital and can greatly benefit from the discovery of effective biomarkers. Researchers have identified novel gene signatures that play pivotal roles in specific CRC types or stages.
View Article and Find Full Text PDFLaparoscopic surgery is associated with increased risk of postoperative peritoneal metastases in T4 colon cancer: a propensity score analysis.
Int J Colorectal Dis
January 2025
Department of Colorectal Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, China.
Background: This study aims to evaluate the postoperative safety, long-term survival, and postoperative peritoneal metastases (PPM) rate associated with laparoscopic surgery (LS) for T4 colon cancer.
Materials And Methods: After propensity score matching, there were 68 patients in each of the LS and Open surgery groups. The primary outcomes were the 3-year OS, DFS, and PPM rates.
A Comprehensive Pan-Cancer Analysis Reveals GRB7 as a Potential Diagnostic and Prognostic Biomarker.
Cureus
December 2024
Genetics/Bioinformatics, Sidra Medicine, Ar-Rayyan, QAT.
Background And Aim: Growth factor receptor-bound protein 7 (GRB7) belongs to a group of adaptor proteins characterized by their conserved multidomain structure. These proteins are involved in cellular signaling pathways that regulate cell growth, proliferation, and differentiation. Alterations in GRB7 expression have been linked to multiple human cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!